Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Open Access
- 15 November 2011
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 187 (10), 4954-4966
- https://doi.org/10.4049/jimmunol.1003477
Abstract
Despite promising results in the use of anti-epidermal growth factor receptor (EGFR) Abs for cancer therapy, several issues remain to be addressed. An increasing emphasis is being placed on immune effector mechanisms. It has become clear for other Abs directed to tumor targets that their effects involve the adaptive immunity, mainly by the contribution of Fc region-mediated mechanisms. Given the relevance of EGFR signaling for tumor biology, we wonder whether the oncogene inhibition could contribute to Ab-induced vaccine effect. In a mouse model in which 7A7 (an anti-murine EGFR Ab) and AG1478 (an EGFR-tyrosine kinase inhibitor) displayed potent antimetastatic activities, depletion experiments revealed that only in the case of the Ab, the effect was dependent on CD4+ and CD8+ T cells. Correspondingly, 7A7 administration elicited a remarkable tumor-specific CTL response in hosts. Importantly, experiments using 7A7 F(ab′)2 suggested that in vivo Ab-mediated EGFR blockade may play an important role in the linkage with adaptive immunity. Addressing the possible mechanism involved in this effect, we found quantitative and qualitative differences between 7A7 and AG1478-induced apoptosis. EGFR blocking by 7A7 not only prompted a higher proapoptotic effect on tumor metastases compared with AG1478, but also was able to induce apoptosis with immunogenic potential in an Fc-independent manner. As expected, 7A7 but not AG1478 stimulated exposure of danger signals on tumor cells. Subcutaneous injection of 7A7-treated tumor cells induced an antitumor immune response. This is the first report, to our knowledge, of a tumor-specific CTL response generated by Ab-mediated EGFR inhibition, suggesting an important contribution of immunogenic apoptosis to this effect.Keywords
This publication has 56 references indexed in Scilit:
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunityImmunologic Research, 2011
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences of the United States of America, 2011
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Immunogenic and tolerogenic cell deathNature Reviews Immunology, 2009
- Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cellsCancer Immunology, Immunotherapy, 2009
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell deathThe EMBO Journal, 2009
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase ActivityCancer Cell, 2008
- How dying cells alert the immune system to dangerNature Reviews Immunology, 2008
- Molecular characteristics of immunogenic cancer cell deathCell Death & Differentiation, 2007
- What is trogocytosis and what is its purpose?Nature Immunology, 2003